AI Agents for Biomedical Research
Phylo is an applied research lab building agentic intelligence to accelerate discovery for every biomedical scientist. We believe AI agents will fundamentally transform how biomedical research is done, enabling faster and more systematic scientific progress.
Our growing team brings together world class researchers and engineers across AI and biology. Backed by a $13.5M seed round led by a16z, Menlo Ventures and Anthropic, and advised by Nobel Prize laureate and pioneering biologists, Phylo is building the next generation of AI systems for the life sciences.
Kexin Huang
Co-founder of Phylo, Inc., a Stanford spin-out focused on agentic AI for biomedical research. Leads development of Biomni Lab, an integrated biology environment.
Yuanhao Qu
Co-founder of Phylo, Inc., established in 2025, specializing in AI-driven bioinformatics solutions.